These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 21640689)

  • 21. Eprosartan effect on fibrinolytic/hemostatic variables in arterial hypertension: a comparative study to losartan.
    Makris TK; Stavroulakis G; Papadopoulos DP; Krespi P; Hatzizacharias A; Zilidis A; Tsoukala C; Votteas VE
    Drugs Exp Clin Res; 2004; 30(3):125-32. PubMed ID: 15366789
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of dihydralazine on renal water and aquaporin-2 excretion in humans.
    Vase H; Lauridsen TG; Bech JN; Pedersen EB
    Scand J Clin Lab Invest; 2009; 69(1):45-51. PubMed ID: 18728933
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Angiotensin receptor blockade and arterial compliance in chronic kidney disease: a pilot study.
    Garg JP; Ellis R; Elliott WJ; Hasabou N; Chua D; Chertow GM; Bakris GL
    Am J Nephrol; 2005; 25(4):393-9. PubMed ID: 16088080
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rationale, design and methods of the OSCAR study: observational study on cognitive function and systolic blood pressure reduction in hypertensive patients.
    Pathak A; Hanon O; Negre-Pages L; Sevenier F;
    Fundam Clin Pharmacol; 2007 Apr; 21(2):199-205. PubMed ID: 17391293
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of eprosartan on mitochondrial membrane potential and H2O2 levels in leucocytes in hypertension.
    Labiós M; Martínez M; Gabriel F; Guiral V; Ruiz-Aja S; Beltrán B; Muñoz A
    J Hum Hypertens; 2008 Jul; 22(7):493-500. PubMed ID: 18385744
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impaired neuronal and vascular responses to angiotensin II in a rabbit congestive heart failure model.
    Nap A; Belterman CN; Mathy MJ; Balt JC; Pfaffendorf M; van Zwieten PA
    J Renin Angiotensin Aldosterone Syst; 2003 Dec; 4(4):220-7. PubMed ID: 14689369
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The effects of eprosartan, an angiotensin II AT1 receptor antagonist, on uric acid excretion in patients with mild to moderate essential hypertension.
    Ilson BE; Martin DE; Boike SC; Jorkasky DK
    J Clin Pharmacol; 1998 May; 38(5):437-41. PubMed ID: 9602957
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of eprosartan on catecholamines and peripheral haemodynamics in subjects with insulin-induced hypoglycaemia.
    Christensen M; Ibsen H; Worck R
    Clin Sci (Lond); 2005 Feb; 108(2):113-9. PubMed ID: 15383007
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A double blind randomized trial to compare the effects of eprosartan and enalapril on blood pressure, platelets, and endothelium function in patients with essential hypertension.
    Leu HB; Charng MJ; Ding PY
    Jpn Heart J; 2004 Jul; 45(4):623-35. PubMed ID: 15353873
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Acute eprosartan-induced intrarenal vasodilation in hypertensive humans is not influenced by dietary sodium intake or angiotensin II co-infusion.
    van Twist DJ; Houben AJ; de Leeuw PW; Kroon AA
    J Hypertens; 2016 Aug; 34(8):1607-14. PubMed ID: 27214088
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sympathetic nerve activity in conscious renal hypertensive rats treated with an angiotensin converting enzyme inhibitor or an angiotensin II antagonist.
    Niederberger M; Aubert JF; Nussberger J; Brunner HR; Waeber B
    J Hypertens; 1995 Apr; 13(4):439-45. PubMed ID: 7629405
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacology of eprosartan, an angiotensin II receptor antagonist: exploring hypotheses from clinical data.
    Brooks DP; Ohlstein EH; Ruffolo RR
    Am Heart J; 1999 Sep; 138(3 Pt 2):246-51. PubMed ID: 10467220
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hemodynamic and cardiac effects of chronic eprosartan and moxonidine therapy in stroke-prone spontaneously hypertensive rats.
    Mukaddam-Daher S; Menaouar A; Paquette PA; Jankowski M; Gutkowska J; Gillis MA; Shi YF; Calderone A; Tardif JC
    Hypertension; 2009 May; 53(5):775-81. PubMed ID: 19273740
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Differentiation in the effects of the angiotensin II receptor blocker class on autonomic function.
    Esler M
    J Hypertens Suppl; 2002 Jun; 20(5):S13-9. PubMed ID: 12184059
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ambulatory monitoring of systolic hypertension in the elderly: Eprosartan/hydrochlorothiazide compared with losartan/hydrochlorothiazide (INSIST trial).
    Ambrosioni E; Bombelli M; Cerasola G; Cipollone F; Ferri C; Grazioli I; Leprotti C; Mancia G; Melzi G; Mugellini A; Mulè G; Palasciano G; Salvetti A; Trimarco B
    Adv Ther; 2010 Jun; 27(6):365-80. PubMed ID: 20556561
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The clinical profile of the angiotensin II receptor blocker eprosartan.
    Hedner T
    J Hypertens Suppl; 2002 Jun; 20(5):S33-8. PubMed ID: 12184062
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of statins on renal sodium and water handling: acute and short-term effects of atorvastatin on renal haemodynamics, tubular function, vasoactive hormones, blood pressure and pulse rate in healthy, normocholesterolemic humans.
    Paulsen L; Holm C; Bech JN; Starklint J; Pedersen EB
    Nephrol Dial Transplant; 2008 May; 23(5):1556-61. PubMed ID: 18065809
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Prospects for pharmacological effects on renin-angiotensin and sympathetic nervous systems in patients with arterial hypertension].
    Chikhladze NM
    Ter Arkh; 2000; 72(12):67-9. PubMed ID: 11201840
    [No Abstract]   [Full Text] [Related]  

  • 39. Effect of angiotensin II receptor blockade on autonomic nervous system function in patients with essential hypertension.
    Krum H; Lambert E; Windebank E; Campbell DJ; Esler M
    Am J Physiol Heart Circ Physiol; 2006 Apr; 290(4):H1706-12. PubMed ID: 16284232
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Risk reduction by preventing stroke: need for blockade of angiotensin II and catecholamines?
    Rupp H
    Curr Med Res Opin; 2007 Nov; 23 Suppl 5():S25-9. PubMed ID: 18093411
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.